Cargando…

Clinical outcomes of salvage treatment in lymph node-positive prostate cancer patients after radical prostatectomy

INTRODUCTION: The optimal salvage treatment strategies for lymph node-positive (LNP) patients after radical surgery have not been clearly defined in prostate cancer with biochemical recurrence or persistence of elevated prostate-specific antigen (PSA). In this study, we compared the clinical outcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Dowook, Kim, Dong-Yun, Kim, Jae-Sung, Hong, Sung Kyu, Byun, Seok-Soo, Lee, Sang Eun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432826/
https://www.ncbi.nlm.nih.gov/pubmed/34506516
http://dx.doi.org/10.1371/journal.pone.0256778
_version_ 1783751246974287872
author Kim, Dowook
Kim, Dong-Yun
Kim, Jae-Sung
Hong, Sung Kyu
Byun, Seok-Soo
Lee, Sang Eun
author_facet Kim, Dowook
Kim, Dong-Yun
Kim, Jae-Sung
Hong, Sung Kyu
Byun, Seok-Soo
Lee, Sang Eun
author_sort Kim, Dowook
collection PubMed
description INTRODUCTION: The optimal salvage treatment strategies for lymph node-positive (LNP) patients after radical surgery have not been clearly defined in prostate cancer with biochemical recurrence or persistence of elevated prostate-specific antigen (PSA). In this study, we compared the clinical outcomes of two different salvage treatments, androgen deprivation therapy (ADT) alone versus ADT with radiotherapy (RT). We also investigated prognostic factors that could support the use of ADT with RT in LNP prostate cancer. MATERIALS AND METHODS: We retrospectively reviewed 94 LNP prostate cancer patients who underwent radical prostatectomy (RP) followed by salvage treatment between 2004 and 2018. Salvage treatments involved either ADT alone or ADT with RT according to the clinical judgment of the physician. We analyzed clinicopathological and treatment factors related to 2(nd) biochemical failure (2(nd) BCF), clinical progression (CP), and progression-free survival (PFS). The cumulative failure after salvage treatment was defined as including both 2(nd) BCF and CP. RESULTS: The median duration of follow-up was 55 months (interquartile range, 35–97 months). Thirty-seven (39.4%) patients were treated with ADT alone, and 57 patients (60.6%) were treated with a combination of ADT with RT. During follow-up period, the incidence of failure after salvage treatment in the ADT alone group and the combined treatment group was 89.2% and 45.6%, respectively (HR, 22.4; 95% CI 5.43–92.1; P < 0.001). The combination of ADT with RT was associated with better 2(nd) BCF and PFS than ADT alone (P = 0.007 and P = 0.015, respectively). In multivariate analyses, number of positive LN ≥ 2 and PSA nadir ≥ 0.005 ng/ml after RP were associated with poor 2(nd) BCF, CP, and PFS after salvage treatment. Salvage by combined ADT plus RT showed better 2(nd) BCF and PFS than ADT alone. Specifically, patients with number of positive LN ≥ 2 or PSA nadir ≥ 0.005 ng/ml after RP showed better 2(nd) BCF (P = 0.004) or PFS (P = 0.011) when treated with ADT plus RT rather than ADT alone. CONCLUSIONS: In patients with LNP prostate cancer, salvage ADT plus RT improved 2(nd) BCF and PFS compared to ADT alone. In particular, when the patients had more than two positive lymph nodes or PSA nadir ≥ 0.005 ng/ml after RP, ADT with RT seems to be a more beneficial salvage treatment resulting in better 2(nd) BCF and PFS.
format Online
Article
Text
id pubmed-8432826
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-84328262021-09-11 Clinical outcomes of salvage treatment in lymph node-positive prostate cancer patients after radical prostatectomy Kim, Dowook Kim, Dong-Yun Kim, Jae-Sung Hong, Sung Kyu Byun, Seok-Soo Lee, Sang Eun PLoS One Research Article INTRODUCTION: The optimal salvage treatment strategies for lymph node-positive (LNP) patients after radical surgery have not been clearly defined in prostate cancer with biochemical recurrence or persistence of elevated prostate-specific antigen (PSA). In this study, we compared the clinical outcomes of two different salvage treatments, androgen deprivation therapy (ADT) alone versus ADT with radiotherapy (RT). We also investigated prognostic factors that could support the use of ADT with RT in LNP prostate cancer. MATERIALS AND METHODS: We retrospectively reviewed 94 LNP prostate cancer patients who underwent radical prostatectomy (RP) followed by salvage treatment between 2004 and 2018. Salvage treatments involved either ADT alone or ADT with RT according to the clinical judgment of the physician. We analyzed clinicopathological and treatment factors related to 2(nd) biochemical failure (2(nd) BCF), clinical progression (CP), and progression-free survival (PFS). The cumulative failure after salvage treatment was defined as including both 2(nd) BCF and CP. RESULTS: The median duration of follow-up was 55 months (interquartile range, 35–97 months). Thirty-seven (39.4%) patients were treated with ADT alone, and 57 patients (60.6%) were treated with a combination of ADT with RT. During follow-up period, the incidence of failure after salvage treatment in the ADT alone group and the combined treatment group was 89.2% and 45.6%, respectively (HR, 22.4; 95% CI 5.43–92.1; P < 0.001). The combination of ADT with RT was associated with better 2(nd) BCF and PFS than ADT alone (P = 0.007 and P = 0.015, respectively). In multivariate analyses, number of positive LN ≥ 2 and PSA nadir ≥ 0.005 ng/ml after RP were associated with poor 2(nd) BCF, CP, and PFS after salvage treatment. Salvage by combined ADT plus RT showed better 2(nd) BCF and PFS than ADT alone. Specifically, patients with number of positive LN ≥ 2 or PSA nadir ≥ 0.005 ng/ml after RP showed better 2(nd) BCF (P = 0.004) or PFS (P = 0.011) when treated with ADT plus RT rather than ADT alone. CONCLUSIONS: In patients with LNP prostate cancer, salvage ADT plus RT improved 2(nd) BCF and PFS compared to ADT alone. In particular, when the patients had more than two positive lymph nodes or PSA nadir ≥ 0.005 ng/ml after RP, ADT with RT seems to be a more beneficial salvage treatment resulting in better 2(nd) BCF and PFS. Public Library of Science 2021-09-10 /pmc/articles/PMC8432826/ /pubmed/34506516 http://dx.doi.org/10.1371/journal.pone.0256778 Text en © 2021 Kim et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Kim, Dowook
Kim, Dong-Yun
Kim, Jae-Sung
Hong, Sung Kyu
Byun, Seok-Soo
Lee, Sang Eun
Clinical outcomes of salvage treatment in lymph node-positive prostate cancer patients after radical prostatectomy
title Clinical outcomes of salvage treatment in lymph node-positive prostate cancer patients after radical prostatectomy
title_full Clinical outcomes of salvage treatment in lymph node-positive prostate cancer patients after radical prostatectomy
title_fullStr Clinical outcomes of salvage treatment in lymph node-positive prostate cancer patients after radical prostatectomy
title_full_unstemmed Clinical outcomes of salvage treatment in lymph node-positive prostate cancer patients after radical prostatectomy
title_short Clinical outcomes of salvage treatment in lymph node-positive prostate cancer patients after radical prostatectomy
title_sort clinical outcomes of salvage treatment in lymph node-positive prostate cancer patients after radical prostatectomy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432826/
https://www.ncbi.nlm.nih.gov/pubmed/34506516
http://dx.doi.org/10.1371/journal.pone.0256778
work_keys_str_mv AT kimdowook clinicaloutcomesofsalvagetreatmentinlymphnodepositiveprostatecancerpatientsafterradicalprostatectomy
AT kimdongyun clinicaloutcomesofsalvagetreatmentinlymphnodepositiveprostatecancerpatientsafterradicalprostatectomy
AT kimjaesung clinicaloutcomesofsalvagetreatmentinlymphnodepositiveprostatecancerpatientsafterradicalprostatectomy
AT hongsungkyu clinicaloutcomesofsalvagetreatmentinlymphnodepositiveprostatecancerpatientsafterradicalprostatectomy
AT byunseoksoo clinicaloutcomesofsalvagetreatmentinlymphnodepositiveprostatecancerpatientsafterradicalprostatectomy
AT leesangeun clinicaloutcomesofsalvagetreatmentinlymphnodepositiveprostatecancerpatientsafterradicalprostatectomy